Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization

被引:7
|
作者
Ventura, Yossi [1 ,2 ]
Carr, Brian I. [3 ]
Kori, Issac [4 ]
Guerra, Vito [5 ]
Shibolet, Oren [1 ,2 ]
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol & Hepatol, Liver Unit, 14 Weizman St, IL-62431 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Dokuz Eylul Univ, Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey
[4] Tel Aviv Med Ctr & Sch Med, Div Imaging, Intervent Radiol, IL-62431 Tel Aviv, Israel
[5] IRCCS Bellis, Dept Clin Trials & Epidemiol, I-70013 Castellana Grotte, Italy
关键词
Hepatocellular carcinoma; Aggressiveness index; Liver function; Transarterial chemoembolization; Survival; GAMMA-GLUTAMYL-TRANSPEPTIDASE; PREDICT SURVIVAL; PROGNOSTIC VALUE; SCORES; EMBOLIZATION; INDEX;
D O I
10.3748/wjg.v24.i15.1641
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate novel predictors of survival in hepatocellular carcinoma (HCC) patients following transarterial chemoembolization (TACE). METHODS One hundred sixty seven patients with un-resectable HCC were retrospectively analyzed to identify factors that might contribute to their HCC biology and aggressiveness. We correlated routine laboratory results (total bilirubin, AST, ALKP, GGTP, albumin etc.) to maximum tumor diameter, number of tumor nodules, portal vein thrombosis and blood alpha-fetoprotein levels. These 4 parameters were previously combined to form an aggressiveness index (AgI). We used The Wilcoxon ranksum (Mann-Whitney), to test the correlation between the AgI categories and liver function parameters. The Cox proportional hazards model was applied to evaluate the categories of AgI associated with overall survival. RESULTS The AgI was strongly correlated with survival in this novel patient population. Three year survival probability for AgI > or < 4 was 42.4% vs 61.8%; p < 0.0863 respectively. Several factors independently correlated with AgI using univariate multiple logistic regression of AgI with 8 laboratory parameters. Lower albumin levels had an OR of 2.56 (95% CI: 1.120-5.863 p < 0.026), elevated Alkaline phosphatase and gamma glutamyl transpeptidase (GGTP) had ORs of 1.01 (95% CI: 1.003-1.026, p < 0.017) and 0.99 (95% CI: 0.99-1.00, p < 0.053) respectively. In a Cox proportional hazard model combining mortality for AgI score and liver function parameters, only GGTP levels and the AgI were independently associated with survival. An AgI > 4 had HR for mortality of 2.18 (95% CI: 1.108-4.310, p < 0.024). GGTP's single unit change had a HR for mortality of 1.003 (95% CI: 1.001-1.006, p < 0.016). These were considered in the final multivariate model with the total cohort. An AgI > 4 had a HR for mortality of 2.26 (95% CI: 1.184-4.327, p < 0.016). GGTP had a HR of 1.003 (95% CI: 1.001-1.004, p < 0.001). CONCLUSION Our study validates the AgI in a new population with un-resectable HCC patients undergoing TACE. The analysis establishes a correlation between GGTP and the AgI.
引用
收藏
页码:1641 / 1649
页数:9
相关论文
共 50 条
  • [1] Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization
    Yossi Ventura
    Brian I Carr
    Issac Kori
    Vito Guerra
    Oren Shibolet
    World Journal of Gastroenterology, 2018, (15) : 1641 - 1649
  • [2] Predictors of Mortality in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Barman, Pranab M.
    Sharma, Pratima
    Krishnamurthy, Venkat
    Willatt, Jonathon
    McCurdy, Heather
    Moseley, Richard H.
    Su, Grace L.
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (11) : 2821 - 2825
  • [3] Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization
    Xiao, Jun
    Li, Guojian
    Lin, Shuhan
    He, Ke
    Lai, Hao
    Mo, Xianwei
    Chen, Jiansi
    Lin, Yuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (03): : 1114 - 1123
  • [4] Predictors of Mortality in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Pranab M. Barman
    Pratima Sharma
    Venkat Krishnamurthy
    Jonathon Willatt
    Heather McCurdy
    Richard H. Moseley
    Grace L. Su
    Digestive Diseases and Sciences, 2014, 59 : 2821 - 2825
  • [5] Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization
    Lee, Sangheun
    Kang, Jung Hyun
    Kim, Do Young
    Ahn, Sang Hoon
    Park, Jun Yong
    Kim, Beom Kyung
    Kim, Seung Up
    Han, Kwang-Hyub
    HEPATOLOGY INTERNATIONAL, 2017, 11 (03) : 292 - 299
  • [6] Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study
    Jeliazkova, Petia
    Umgelter, Andreas
    Braren, Rickmer
    Kaissis, Georgios
    Mustafa, Mona
    Einwaechter, Henrik
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (08) : 1036 - 1041
  • [7] Retrospective Analysis of Aberrant Hepatic Artery in 1250 Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Du, Dongdong
    Zhang, Zhenhai
    Wang, Xinxing
    Ma, Mingze
    Wu, Naishi
    ANNALI ITALIANI DI CHIRURGIA, 2024, 95 (03) : 364 - 373
  • [8] Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Wu, Jie
    Song, Lei
    Zhao, Dan-Yi
    Guo, Bing
    Liu, Jing
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (31) : 10960 - 10968
  • [9] Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre
    Eltawil, Karim M.
    Berry, Robert
    Abdolell, Mohamed
    Molinari, Michele
    HPB, 2012, 14 (03) : 162 - 170
  • [10] ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization
    Jia, Ke-Feng
    Wang, Hao
    Yu, Chang-Lu
    Yin, Wei-Li
    Zhang, Xiao-Dong
    Wang, Fang
    Sun, Cheng
    Shen, Wen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (05) : 490 - 497